Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a topical combination medication containing metronidazole, diltiazem, and lidocaine used primarily for the treatment of acute anal fissures. The combination provides multiple therapeutic benefits: metronidazole acts as an antibiotic effective against anaerobic bacteria that may cause subclinical infection in anal fissures, diltiazem functions as a calcium channel blocker to relax the internal anal sphincter, and lidocaine provides local anesthetic effects to reduce pain. Clinical studies have shown that this combination therapy offers superior outcomes compared to conventional treatments alone, including faster pain reduction, improved healing rates, and decreased need for surgical intervention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metronidazole + diltiazem + lidocaine.